Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment

Ling Yang, Qian Ning, and Sheng-song Tang

1Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, and Institute of Pharmacy & Pharmacology, University of South China, Hengyang 421001, China
2Hunan Province Key Laboratory for Antibody-Based Drug and Intelligent Delivery System, School of Pharmaceutical Sciences, Hunan University of Medicine, Huaihua 418000, China
3Department of Pharmacy, The First People’s Hospital of Huaihua City, Huaihua 418000, China
4College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha 410000, China

Correspondence should be addressed to Sheng-song Tang; tangss_submit@163.com

Received 28 January 2022; Accepted 2 March 2022; Published 18 March 2022

Academic Editor: Dawei Cui

Copyright © 2022 Ling Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

With the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an important component of cancer immunotherapy. The therapy with the cancer vaccine is promising cancer immunotherapy capable of cancer prevention. Cytokine therapy is one of the pillars of cancer immunotherapy. Oncolytic immunotherapy is a promising novel component of cancer immunotherapy, which with significantly lower incidence of serious adverse reactions. The recent positive results of many clinical trials with cancer immunotherapy may herald good clinical prospects. But there are still many challenges in the broad implementation of immunotherapy. Here, we center on recent progress made within the last 5 years in cancer immunotherapy. And we discuss the theoretical background, as well as the opportunities and challenges of cancer immunotherapy.

1. Introduction

Cancer is a devastating disease, which has been one of the main threats to human health. Worldwide, nearly 10 million people will die from cancer in 2020 [1]. Surgery, radiotherapy, and chemotherapy are the three traditional treatments of cancer, but these methods have certain limitations, such as traumatic, low targeting, serious toxicity, and drug resistance [2]. Furthermore, they often fail to provide long-term survival benefits for patients with advanced solid tumors, according to clinical practice. Along with the deepening research of tumor immunology, cell biology, and molecular technology, scientists find that the tumor microenvironment (TME) is immunosuppressive. Studies have shown that cancer development and metastasis are highly positively correlated with immunosuppression [3]. Cancer immunotherapy, which harnesses the body’s immune system to eradicate tumor cells, is widely researched. The components and brief mechanisms of cancer immunotherapy are shown in Figure 1. Thousands of clinical trials have proved that cancer immunotherapy is becoming a powerful new approach to cancer treatment. Despite the promising prospects, the clinical application of immunotherapy still faces some challenges in terms of effectiveness and safety. In this review, the five cancer immunotherapies mentioned above are overviewed, and their clinical status, advantages, and disadvantages are discussed.

2. Immune Checkpoint Blockade Therapy

Immune checkpoints refer to immunosuppressive molecules. Physiologically, immune checkpoints are important for maintaining immune tolerance regulating immune
responses and preventing tissue damage. Nonetheless, the high expression of checkpoints can mediate tumor immune evasion by inhibiting immune cell function, in the development and activation of tumors [4]. Fortunately, immune checkpoint inhibitors can block the transmission of immunosuppressive signals, then restore or enhance the body’s antitumor immune response.

The main representatives of immune checkpoints are cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein1 (PD-1), and programmed cell death ligand1 (PD-L1). CTLA-4 is expressed on the activated CD8+ and CD4+ T cells. During the early activation of T cells, CTLA-4 competes with the costimulatory receptor CD28 to bind to ligands B7-1 and B7-2 expressed on the antigen-presenting cells (APCs). Then inducing the downstream negative regulation of immune response, which leads to the suppression of T cell proliferation and the IL-2 secretion [5, 6]. It ultimately inhibits the adequate immune response to tumor cells. Like the CTLA-4, PD-1 is also a transmembrane protein expressed on T cells. PD-L1 is one of its ligands, which can be expressed on tumor cells, APCs, and T cells themselves. When PD-1 binds to PD-L1, it reduces the response of T cells to T cell receptor (TCR) stimulation signals through PI3K-AKT and JAK-STAT signaling pathways [7, 8]. Leading to the suppressive antitumor T cell responses, the brief antitumor mechanism of CTLA-4 and PD-1/PD-L1 blocking antibodies is shown in Figure 2.

Thus far, one anti-CTLA-4 antibody (ipilimumab), three anti-PD-1 antibodies (pembrolizumab, nivolumab, and cemiplimab), and three anti-PD-L1 antibodies (atezolizumab, avelumab, and durvalumab) for the treatment of different malignancies have been approved by the United States Food and Drug Administration (FDA) [9]. Ipilimumab, a monoclonal antibody directed against CTLA-4, was approved by the FDA for patients with metastatic melanoma in 2011 [10]. It is the first clinically approved immune checkpoint inhibitor. When ipilimumab was used to treat metastatic melanoma, 20% of patients survived more than 4 years, and a small percentage of patients survived for 10 years or more [11]. Ipilimumab is also widely used in the treatment of tumors such as lung cancer, kidney cancer, and prostate cancer [12]. But the effectiveness is less than metastatic melanoma. Efficiencies below 10% are usually unsatisfactory. Generally speaking, the antitumor treatment efficiency of PD-1/PD-L1 blockers is better than CTLA-4 blockers. In patients with advanced melanoma, pembrolizumab was found to be more effective than ipilimumab at extending progression-free survival and overall survival [13]. Nivolumab, for the patients with classic Hodgkin’s lymphoma, the treatment response rate is more than 80% [14]. And for many patients with cancer, the curative effect of PD-1/PD-L1 blocking antibody is above 10%. In addition to the antitumor efficacy, the adverse effects cannot be ignored. The most common are immune-related adverse events (irAEs), such as rash, colitis, diarrhea, hepatotoxicity, and endocrinopathies. There are even occasional fatal adverse events [15]. The clinical promotion of immune checkpoint inhibitors is limited by relatively low response rates and relatively high treatment-related toxicity. Some biomarkers can predict the therapeutic effects and the adverse reactions of immune checkpoint blockade therapy. It brings hope to the widespread application of immune checkpoint blocking therapy. Higher mutational load and neoantigen loads are significantly associated with the clinical benefit of anti-CTLA-4 antibodies [16]. Tumor PD-L1 expression was significantly associated with the overall response rate (ORR) of PD-1/PD-L1 inhibitors. The ORR of the PD-L1 positive group was 34.1% while the PD-L1 negative group was 19.9% [17]. These biomarkers will be helpful in the identification of cancer patients who can benefit from the immune checkpoint blockade therapy. Meanwhile, the increase in expression of CD177 and CEACAM1 is closely related to colitis after ipilimumab treatment [18]. That is to say, for patients treated with ipilimumab, CD177 and CEACAM1 can help to take countermeasures in advance to reduce the damage caused by immune-related colitis. In addition, many potential biomarkers are useful to predict the side effects and therapeutic efficacy; for instance, mismatch repair (MMR) deficiency, interferon-γ (IFN-γ) related mRNA profile, and T-cell invigoration to tumor burden ratio [19–21]. When the predictive effect of biomarkers is verified in a larger patient cohort, precision medicine, and immune checkpoint blockade therapy will take a new step.

Figure 1: Components and brief mechanisms of cancer immunotherapy.

3. Adoptive Cell Therapy

Adaptive cell therapy (ACT) extracts immune-competent cells from cancer patients, genetically modifies or massively
expands immunocompetent cells in vitro to increase immune activity, and then reinjects them into cancer patients to enhance the body’s anti-tumor immune function [22, 23]. Immunocompetent cells include lymphokine-activated killer cells (LAK), chimeric antigen receptor-modified T (CAR-T) cells, chimeric antigen receptor-modified nature killer cells (CAR-NK), T cell receptor-modified T (TCR-T) cells, cytokine activation killing (CIK) cells, and tumor-infiltrating lymphocytes (TILs). The use of TILs, TCR-T cells, and CAR-T cells is the most studied of all ACT therapies. And the mechanisms of them are shown in Figure 3.

Rosenberg et al. first reported that TILs could promote tumor regression in patients with metastatic melanoma [24]. In metastatic melanoma patients receiving ACT with TILs, the objective response rate is 40-50%, including 10-20% complete tumor regression has been reported many times [25–27]. Whereas amphiﬁtable antitumor TILs are only found in a few types of tumors, and the expansion process of TILs is complex [28]. The successful use of CD137 to separate and select TILs gives us a good idea for enriching tumor-reactive TILs [29]. The key to the ACT with TILs is to improve the quality and characterization of T cells, and how to simplify the method for obtaining tumor-specific T cells will be the focus of the next research.

The genome-editing method that won the 2020 Nobel Prize in Chemistry also promotes the development of adoptive cell therapy. Being frequently exposed to foreign nucleic acids, bacteria and archaea have developed an ingenious adaptive defense system, called CRISPR-Cas [30]. ACT with genetically modiﬁed T cells can recognize tumor antigens through related tumor-reactive TCR or CAR. A study of 20 patients with advanced myeloma conﬁrmed that NY-ESO-1-speciﬁc TCR-T cells mediate sustained antigen-speciﬁc antitumor effects [31]. In a pilot trial, after NY-ESO-1 treatment, the 3-year and 5-year overall survival rates of patients with synovial cell sarcoma were estimated to be 38% and 14%, respectively, while the corresponding estimated survival rates for melanoma patients were 33%. But two patients developed cardiogenic shock after an infusion of TCR-T cells and died within a few days [32]. ACT with TCR-T shows some efﬁcacy against the tumor. But it has certain individual differences, which not only lead to differences in antitumor efﬁcacy but may even threaten the lives of patients. In order to reduce toxicity, it is extremely beneﬁcial to identify personalized targetable antigens that can be expressed on tumors but not on healthy tissues. Neoantigens due to tumor-speciﬁc mutations will surely become a hot spot for the future. Besides, MHC class I complexes are usually downregulated in cancer cells [33]. TILs and TCR modiﬁed T cells recognize antigen in an MHC-dependent manner also limit their clinical application. The antigen recognition ability of CAR-T cells is based on tumor surface proteins and can eliminate the limitations of the MHC to present antigens.

ACT with CAR-T cells makes use of transgenic technology to express CAR in T cells, which usually consists of an extracellular antigen binding moiety (such as antibody scFv) fused to an intracellular signaling domain for T cell activation [34, 35]. The transformation of the signal domain in the CAR structure enables CAR to play a variety of T cell functions, such as ampliﬁcation, cytokine secretion, and tissue selectivity [36, 37]. It can further expand the scope and efﬁcacy of ACT. Extracellular glycoprotein CD19 is the most common cellular target for ACT with CAR-T cells, which is a marker of B cell tumors. CD19 CAR-T has been successfully used to treat patients with refractory chronic lymphoma. The efﬁcacy of the three patients was more than half a year, and 2 of them were completely relieved [38]. The CAR-T therapies (tisagenlecleucel and axicabtagene ciloleucel) for adult and pediatric B cell malignancies are approved by the FDA in 2017 [39, 40]. Besides, trials of CAR-T treatment targeting CD22 [41] and CD30 [42] are also underway. And the new cellular targets for ACT with CAR-T cells bring new hope for reversing relapse. CAR-T cell therapy is not only a promising therapy to overcome hematological tumors but also a method with great therapeutic potential in solid tumors. Although previous studies have shown poor results and varying degrees of toxicity. A recent CAR-T cell targeting IL-13Ra2 has induced complete
Cytokines are polypeptides, proteins, or glycoproteins with a molecular weight usually under 30 kDa, which are involved in transmitting the signals of cell proliferation, differentiation, inflammation, or anti-inflammatory [47, 48]. The main feature of cytokine therapy is that it can directly promote the growth and immune activity of immune cells.

Interleukin-2 (IL-2) is critical to the activation, growth, and survival of T cells and NK cells and maintains the delicate balance between autoimmunity and antineoplasms 3 surveillance. It has been proved that the high-dose IL-2 (HDIL-2) has the superior antitumor effect while the low doses of IL-2 can induce the proliferation of suppressor T cells (Tregs), which suppress the activation of the immune system, weakening the antitumor efficacy. The FDA approved HDIL-2 for the therapy of metastatic renal cell carcinoma (RCC) in 1992 and the therapy of metastatic melanoma in 1998 [49, 50]. Nevertheless, the high dose of IL-2 can cause the capillary leak syndrome, which is featured by multiorgan damage, such as hypotension, lung edema, and renal failure resulting from extravasation of fluid into the organs. According to the latest research, FSD13, produced by a selective amino acid replacement, can selectively inhibit the IL-2 mediated Treg proliferation and increase the IL-2 function of stimulating the antitumor immune cell [51]. It provides a new method to reduce systemic toxicity and improve the efficacy of IL-2-based immunotherapy.

Interferon-alpha (IFN-α) is another representative cytokine that can play an important role in the body’s immune regulation and antitumor immune response. IFN-α not only activates immune cells directly but also effectively activates the systemic immune response by reversing the immune-suppression of effector mesenchymal stromal cells (MSCs) [52]. IFN-α was approved in 1986 for the therapy of hairy cell leukemia and in 1995 for the therapy of melanoma [53, 54]. However, the use of IFN-α can be quite toxic, especially at high doses. Elevated liver enzymes, neutropenia, thrombocytopenia, and leukopenia are common toxicities. Besides, many other cytokines like interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-21 (IL-21), granulocyte-macrophage colony-stimulating factor (GM-CSF), transforming growth factor-beta (TGF-β), and tumor necrosis factor-alpha (TNF-α) are underinvestigated.

Of note, the short half-life, the relatively low objective response rates, and high toxicity associated with high doses of some cytokines administration have seriously limited the widespread research and clinical application of cytokines [55, 56]. To break the limitations, many methods are taken. Cytokines injection into tumor lesions was tried, and cytokine fusion proteins were engineered to enhance the antitumor effect [57–59].

5. Cancer Vaccines

Cancer vaccine takes advantage of tumor-associated antigens (TAA) or tumor-specific antigens (TSA) to stimulate the immune system, especially a robust and long-lasting immune response of CD8$^+$ T cells to inhibit the growth, metastasis, and recurrence of tumor cells [60]. There are numerous different platforms of the cancer vaccine, mainly including cell-based, RNA-based, DNA-based, and protein/peptide-based preparations [61]. According to the clinical use of cancer vaccines, they are divided into two categories: preventive and therapeutic. The preventive cancer vaccine aims to prevent tumor occurrence by inducing immune response while the therapeutic cancer vaccines are designed to eradicate tumor cells by inducing or enhancing the tumor-specific immunoreactions [62]. Currently, the relatively successful preventive cancer vaccines are cervical cancer vaccines by targeting human papillomavirus (HPV). The approved cervical vaccines Gardasil and Cervarix resulted in the reduction of the prevalence of cervical intraneoplasia in young women with the administration of the vaccine during adolescence [63, 64]. However, they are mostly invalid once suffering from cancer or chronic infection with HPV. Therefore, not only preventive cancer vaccines but also therapeutic cancer vaccines are needed. It is inspiring that sipuleucel-T (Provenge) can extend the overall viability of patients with hormone-resistant prostate cancer by an average of 3 months [65]. And it is approved by the FDA for metastatic castration-resistant prostate cancer. Although after using cancer vaccines, many experiments have shown that some patients with advanced cancer have good clinical effects,
the partial remission (PR) or complete remission (CR) rate is basically below 10%, or even below 5%. So far, in phase 3 randomized trials, there is no other therapeutic cancer vaccine has yet shown noteworthy clinical efficacy except the sipuleucel-T [66–69].

The efficacy of the cancer vaccine is primarily dependent on immunogenicity, host immunosuppression, preferential expression of tumor antigen, and the delivery of cancer vaccine [70]. The tumor-specific antigens, also known as neoantigens, are ideal cancer vaccine targets, due to the highly immunogenic, lower risk of self-tolerance, less common tumor antigen deletions, and lower risk of autoimmune reactions [71, 72]. And next-generation sequencing (NGS) brings a technological breakthrough to the screening of neoantigens. In a study of 13 patients with melanoma who had no clinically visible residual surgery after surgery, 8 patients had complete tumor disappearance and no recurrence after receiving the personalized RNA mutanome vaccine [73]. In 6 melanoma patients who had received personal neoantigen vaccines, 4 patients had complete tumor disappearance, no recurrence, and 2 patients had tumor recurrence but were completely relieved after treatment with the programmed death receptor 1 (PD1) monoclonal antibody (pembrolizumab) [74]. Based on these studies, individualized cancer vaccines have strong theoretical support, and new approaches to individualized anticancer immunotherapy have been opened up. However, the preparation process of personalized cancer vaccines is complicated and the preparation time is long, which needs to be further explored and solved. In detail, rapid screening of highly immunogenic neoantigens, selection of appropriate immune adjuvants, rapid verification of vaccine potency, and shortening of preparation time will be the focus of future cancer personalized vaccine research.

6. Oncolytic Immunotherapy

Oncolytic immunotherapy is based on oncolytic viruses (OVs). OVs can lead to lysis of the tumor cells and the activation of the innate and adaptive immune response, by specifically replicating in cancer cells without damaging normal cells [75, 76]. That is to say, oncolytic immunotherapy can play the antitumor effect by directly lysing tumors and stimulating the body’s immunity. It fights malignancies without dependence on specific antigen expression, which makes it superior to other immunotherapy approaches. In 2015, a genetically engineered oncolytic herpes simplex virus (HSV), talimogene laherparepvec (T-VEC), was approved for the treatment of advanced melanoma by the United States FDA [77, 78].

However, the immune response activated by OVs is a double-edged sword, because it consists of the antitumor effect and the viral immune response [79]. On the one hand, OVs stimulate the immune system to recognize cancer cells and activate antitumor immunity mainly by inducing immunogenic cell death (ICD) of them [80–82]. On the other hand, OVs are identified by the immune system as causative agents. The immune system generates the antiviral response, which could diminish the efficacy of the antitumor by clearing the virus prematurely [79, 83]. The intratumoral injection is adopted for its safety in oncolytic immunotherapy. It can prevent the humoral immunity from removing viruses and repeated intratumoral injection can induce a strong immune response against the tumor [84]. Whereas the majority of cancers are metastatic, intravenous injection is an ideal method of delivery for the disseminated tumors [85, 86]. How to avoid the early elimination of OVs caused by antiviral response becomes especially important. Moreover, we cannot simply remove the antiviral response, because it can help to reverse the tumor-mediated suppression of immunity [87]. Perfect oncolytic immunotherapy requires a desirable balance of immune responses between antitumor and antiviral. Numerous approaches have been studied to obtain the above balance and the greatest therapeutic effect, such as way like genetic modification [88–90], depleting antibodies [91], polymer coating [92], and carrier cells [93].

7. Conclusion and Prospects

The immune system can specifically attack cancer cells, coupled with its ability to adapt to progressive tumors, and its long-lasting memory function, making cancer immunotherapy the most promising therapy for durable control of cancer. Remarkable success has been achieved in cancer immunotherapy. Several cancer immunotherapy agents have been approved for the treatment of many types of malignancies with durable and impressive clinical responses. But the toxic side effects, insufficient immune responses, and the immunosuppressive environment of tumors create great challenges to therapeutic efficiency. Our group has long been committed to the research and development of antitumor drugs such as immune evasion mechanism of tumor cells [94], screening, and delivery of antitumor drugs [95]. And developing a targeted drug delivery system to improve the efficiency of the cancer immunotherapy agents in the next direction of our efforts.

In addition, there are many promising research directions, such as screening more suitable immunotherapy targets to reduce toxic effects, finding reliable biomarkers to guide the specific immunotherapy of cancer, and combining immunotherapy with other appropriate cancer therapies to expand the scope of application. Clinical trials of cancer immunotherapy continue to expand the indications for these therapies and explore new ways to harness the immune system to treat cancer. The prospects of cancer immunotherapy research are immeasurable, and its extensive development and rapid advancement bring new dawn and hope to cure cancer.

Conflicts of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We are very grateful for the support of the Hunan Provincial Science and Technology Plan Key Projects of China.
(2017SK2183), Hunan Provincial Natural Science Foundation of China (2019J50416), and Scientific Research Fund of Hunan Provincial Education Department (18C1133).

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.

[2] S. A. de Oliveira, R. Borges, D. dos Santos Rosa et al., "Strategies for cancer treatment based on photonic nanomedicine," Materials, vol. 14, no. 6, p. 1435, 2021.

[3] G. Giannone, E. Ghisoni, S. Genta et al., "Immuno-metabolism and microenvironment in cancer: key players for immunotherapy," International Journal of Molecular Sciences, vol. 21, no. 12, p. 4414, 2020.

[4] Y. Xu, Z. Gao, R. Hu et al., "PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy," Journal for Immunotherapy of Cancer, vol. 9, no. 10, p. e002699, 2021.

[5] Z. N. Willsmore, B. G. T. Coumbe, S. Crescioli et al., "Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action," European Journal of Immunology, vol. 51, no. 3, pp. 544–556, 2021.

[6] S. Chikuma, "CTLA-4, an essential immune-checkpoint for T-cell activation," Current Topics in Microbiology and Immunology, vol. 410, pp. 99–126, 2017.

[7] J. Barclay, I. Creswell, and J. Leon, "Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway," Archivos espanoles de urologia, vol. 71, no. 4, pp. 393–399, 2018.

[8] X. Jiang, J. Wang, X. Deng et al., "Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape," Molecular Cancer, vol. 18, no. 1, p. 10, 2019.

[9] K. M. Hargadon, C. E. Johnson, and C. J. Williams, "Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors," International Immunopharmacology, vol. 62, pp. 29–39, 2018.

[10] C. Robert, L. Thomas, I. Bondarenko et al., "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma," The New England Journal of Medicine, vol. 364, no. 26, pp. 2517–2526, 2011.

[11] D. Schadendorf, F. S. Hodi, C. Robert et al., "Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma," Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 33, no. 17, pp. 1889–1894, 2015.

[12] V. Grunwald, "T-cell checkpoint inhibitors in metastatic renal cell carcinoma," Current Opinion in Urology, vol. 25, no. 5, pp. 411–415, 2015.

[13] C. Robert, J. Schachter, G. V. Long et al., "Pembrolizumab versus ipilimumab in advanced melanoma," The New England Journal of Medicine, vol. 372, no. 26, pp. 2521–2532, 2015.

[14] S. M. Ansell, A. M. Lesokhin, I. Borrello et al., "PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma," The New England Journal of Medicine, vol. 372, no. 4, pp. 311–319, 2015.

[15] D. Y. Wang, J. E. Salem, J. V. Cohen et al., "Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis," JAMA Oncology, vol. 4, no. 12, pp. 1721–1728, 2018.

[16] E. M. Van Allen, D. Miao, B. Schilling et al., "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma," Science, vol. 350, no. 6257, pp. 207–211, 2015.

[17] L. Carbognin, S. Pilotto, M. Milella et al., "Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers," PloS one, vol. 10, no. 6, p. e0130142, 2015.

[18] V. Shahabi, D. Berman, S. D. Chasalow et al., "Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events," Journal of Translational Medicine, vol. 11, no. 1, p. 75, 2013.

[19] E. A. Sloan, K. L. Ring, B. C. Willis, S. C. Modesitt, and A. M. Mills, "PD-L1 expression in mismatch repair-deficient endometrial carcinomas, including Lynch syndrome-associated and MLH1 promoter hypermethylated tumors," The American Journal of Surgical Pathology, vol. 41, pp. 326–333, 2017.

[20] M. Ayers, J. Lunceford, M. Nebozhyn et al., "IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade," The Journal of Clinical Investigation, vol. 127, no. 8, pp. 2930–2940, 2017.

[21] A. C. Huang, M. A. Postow, R. J. Orlowski et al., "T-cell invigoration to tumour burden ratio associated with anti-PD-1 response," Nature, vol. 545, no. 7652, pp. 60–65, 2017.

[22] S. Guedan, M. Ruella, and C. H. June, "Emerging cellular therapies for cancer," Annual Review of Immunology, vol. 37, pp. 145–171, 2019.

[23] G. Xue, N. Zheng, J. Fang et al., "Adaptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells," Cancer cell, vol. 39, no. 12, pp. 1610–1622.e9, 2021.

[24] S. A. Rosenberg, B. S. Packard, P. M. Aebersold et al., "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma," The New England Journal of Medicine, vol. 319, no. 25, pp. 1676–1680, 1988.

[25] M. J. Besser, R. Shapira-Frommer, O. Itzhaki et al., "Adaptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies," Clinical cancer research: an official journal of the American Association for Cancer Research, vol. 19, no. 17, pp. 4792–4800, 2013.

[26] R. Andersen, M. Donia, E. Ellebaek et al., "Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen," Clinical cancer research: an official journal of the American Association for Cancer Research, vol. 22, no. 15, pp. 3734–3745, 2016.

[27] S. A. Rosenberg, J. C. Yang, R. M. Sherry et al., "Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy," Clinical cancer research: an official journal of the American Association for Cancer Research, vol. 22, no. 13, pp. 4550–4557, 2011.

[28] J. R. Yannelli, C. Hyatt, S. McConnell et al., "Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience," International Journal of Cancer, vol. 65, no. 4, pp. 413–421, 1996.

[29] S. Seliktar-Ofir, E. Merhavi-Shoham, O. Itzhaki et al., "Selection of shared and neoantigen-reactive T cells for adoptive cell therapy based on CD137 separation," Frontiers in Immunology, vol. 8, p. 1211, 2017.
[30] A. Butiuc-Keul, A. Farkas, R. Carpa, and D. Iordache, "CRISPR-Cas system: the powerful modulator of accessory genomes in prokaryotes," *Microbial Physiology*, pp. 1–16, 2021.

[31] A. P. Rapoport, E. A. Stadtmauer, G. K. Binder-Scholl et al., "NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma," *Nature Medicine*, vol. 21, no. 8, pp. 914–921, 2015.

[32] P. F. Robbins, S. H. Kassim, T. L. N. Tran et al., "A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response," *Clinical cancer research: an official journal of the American Association for Cancer Research*, vol. 21, no. 5, pp. 1019–1027, 2015.

[33] S. A. Rosenberg and N. P. Restifo, "Adaptive cell transfer as personalized immunotherapy for human cancer," *Science*, vol. 348, no. 6230, pp. 62–68, 2015.

[34] Z. Wang, Z. Wu, Y. Liu, and W. Han, "New development in CAR-T cell therapy," *Journal of Hematology & Oncology*, vol. 10, no. 1, p. 53, 2017.

[35] Z. Eshhar, T. Waks, G. Gross, and D. G. Schindler, "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 90, no. 2, pp. 720–724, 1993.

[36] C. Y. Wu, K. T. Roybal, E. M. Puchner, J. Onuffer, and W. A. Lim, "Remote control of therapeutic T cells through a small molecule-gated chimeric receptor," *Science*, vol. 350, no. 6258, pp. 1019–1027, 2015.

[37] L. Morsut, K. T. Roybal, X. Xiong et al., "Engineering customized cell sensing and response behaviors using synthetic notch receptors," *Cell*, vol. 164, no. 4, pp. 780–791, 2016.

[38] D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, and C. H. June, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia," *The New England Journal of Medicine*, vol. 365, no. 8, pp. 725–733, 2011.

[39] F. L. Locke, S. S. Neelapu, N. L. Bartlett et al., "Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma," *Molecular therapy: the journal of the American Society of Gene Therapy*, vol. 25, no. 1, pp. 285–295, 2017.

[40] S. L. Maude, T. W. Laetsch, J. Buechner et al., "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia," *The New England Journal of Medicine*, vol. 378, no. 5, pp. 439–448, 2018.

[41] J. Pan, Q. Niu, B. Deng et al., "CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia," *Leukemia*, vol. 33, no. 12, pp. 2854–2866, 2019.

[42] C. A. Ramos, B. Ballard, H. Zhang et al., "Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes," *Journal of Clinical Investigation*, vol. 127, no. 9, pp. 3462–3471, 2017.

[43] C. E. Brown, D. Alizadeh, R. Starr et al., "Regression of glioblastoma after chimeric antigen receptor T-cell therapy," *The New England Journal of Medicine*, vol. 375, no. 26, pp. 2561–2569, 2016.

[44] D. W. Lee, J. N. Kochenderfer, M. Stetler-Stevenson et al., "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase I dose-escalation trial," *Lancet*, vol. 385, no. 9967, pp. 517–528, 2015.

[45] A. D. Posey Jr., R. D. Schwab, A. C. Boesteanu et al., "Engineered CAR T cells targeting the cancer-associated Nglycoform of the membrane mucin MUC1 control adenocarcinoma," *Immunity*, vol. 44, no. 6, pp. 1444–1454, 2016.

[46] V. D. Fedorov, M. Themeli, and M. Sadelain, "PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses," *Science translational medicine*, vol. 5, 2013.

[47] P. Berraondo, M. F. Sanmamed, M. C. Ochoa et al., "Cytokines in clinical cancer immunotherapy," *British Journal of Cancer*, vol. 120, no. 1, pp. 6–15, 2019.

[48] L. Bonati and L. Tang, "Cytokine engineering for targeted cancer immunotherapy," *Current Opinion in Chemical Biology*, vol. 62, pp. 43–52, 2021.

[49] G. Fye, R. I. Fisher, S. A. Rosenberg, M. Sznol, D. R. Parkinson, and A. C. Louie, "Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy," *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 13, no. 3, pp. 688–696, 1995.

[50] M. B. Atkins, M. T. Lotze, J. P. Dutcher et al., "High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993," *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 17, no. 7, pp. 2105–2116, 1999.

[51] X. Chen, X. Ai, C. Wu et al., "A novel human IL-2 mune with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2," *Cell Death & Disease*, vol. 9, no. 10, pp. 989, 2018.

[52] P. Shou, Q. Chen, J. Jiang et al., "Type I interferons exert antitumor effect via reversing immunosuppression mediated by mesenchymal stromal cells," *Oncogene*, vol. 35, no. 46, pp. 5953–5962, 2016.

[53] H. M. Golomb, A. Jacobs, A. Fefer et al., "Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients," *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 4, no. 6, pp. 900–905, 1986.

[54] J. M. Kirkwood, M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum, "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684," *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, vol. 14, no. 1, pp. 7–17, 1996.

[55] D. Davar, F. Ding, M. Saul et al., "High-dose interleukin-2 (HD II-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute," *Journal for Immunotherapy of Cancer*, vol. 5, no. 1, p. 74, 2017.

[56] S. Lee and K. Margolin, "Cytokines in cancer immunotherapy," *Cancers*, vol. 3, no. 4, pp. 3856–3893, 2011.

[57] J. Fioravanti, I. González, J. Medina-Echeverz et al., "Type I interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties," *Hepatology*, vol. 53, no. 6, pp. 1864–1873, 2011.

[58] G. C. Sim and L. Radvanyi, "The IL-2 cytokine family in cancer immunotherapy," *Cytokine & Growth Factor Reviews*, vol. 25, no. 4, pp. 377–390, 2014.
Y. Xu, L. C. Carrascosa, Y. A. Yeung et al., “An engineered IL15 cytokine mutein fused to an anti-PD1 improves intratumoral T-cell function and antitumor immunity,” Cancer Immunology Research, vol. 9, no. 10, pp. 1141–1157, 2021.

P. A. Ott and C. J. Wu, “Cancer vaccines: steering T cells down the right path to eradicate tumors,” Cancer Discovery, vol. 9, no. 4, pp. 476–481, 2019.

S. J. Paston, V. A. Brentville, P. Symonds, and L. G. Durrant, “Cancer vaccines, adjuvants, and delivery systems,” Frontiers in Immunology, vol. 12, article 627932, 2021.

M. Saxena, S. H. van der Burg, C. J. M. Melief, and Y. Xu, L. C. Carrascosa, Y. A. Yeung et al., “First oncolytic virus approved for melanoma immunotherapy,” Oncoimmunology, vol. 5, no. 1, article e1115641, 2016.

M. Arbyn, L. Xu, C. Simoens, P. P. Martin-Hirsch, and S. J. Paston, V. A. Brentville, P. Symonds, and L. G. Durrant, “Cancer vaccines: steering T cells down the right path to eradicate tumors,” Anticancer Research, vol. 21, no. 6, pp. 360–378, 2021.

M. Arbyn, L. Xu, C. Simoens, P. P. Martin-Hirsch, and Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, “Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors,” The Cochrane database of systematic reviews, vol. 2020, no. 3, p. CD009069, 2020.

S. L. Osborne, S. N. Tabrizi, J. M. Brotherton et al., “Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program,” Vaccine, vol. 33, no. 1, pp. 201–208, 2015.

P. W. Kantoff, C. S. Higano, N. D. Shore et al., “sipuleucel-T immunotherapy for castration-resistant prostate cancer,” The New England Journal of Medicine, vol. 363, no. 5, pp. 411–422, 2010.

R. Levy, K. N. Ganjoo, J. P. Leonard et al., “Active idiotypic vaccination versus control immunotherapy for follicular lymphoma,” Journal of Clinical Oncology, vol. 32, no. 17, pp. 1797–1803, 2014.

J. F. Vansteenkiste, B. C. Cho, T. Vanakesa et al., “Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial,” The Lancet Oncology, vol. 17, no. 6, pp. 822–835, 2016.

B. I. Rini, A. Stenzl, R. Zdrojowy et al., “IMA901, a multipetide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial,” The Lancet Oncology, vol. 17, no. 11, pp. 1599–1611, 2016.

K. K. Wong, W. A. Li, D. J. Mooney, and G. Dranoff, “Advances in therapeutic cancer vaccines,” Advances in Immunology, vol. 130, pp. 191–249, 2016.

J. Schlom, J. W. Hodge, C. Palena et al., “Therapeutic cancer vaccines,” Advances in Cancer Research, vol. 121, pp. 67–124, 2014.

E. Stronen, M. Toebes, S. Kelderman et al., “Targeting of cancer neoantigens with donor-derived T cell receptor repertoires,” Science, vol. 352, no. 6291, pp. 1337–1341, 2016.

C. J. Cohen, J. J. Gartner, M. Horovitz-Fried et al., “Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes,” The Journal of Clinical Investigation, vol. 125, no. 10, pp. 3981–3991, 2015.

U. Sahin, E. Derhovanessian, M. Miller et al., “Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer,” Nature, vol. 547, no. 7662, pp. 222–226, 2017.

P. A. Ott, Z. Hu, D. B. Keskin et al., “An immunogenic personal neoantigen vaccine for patients with melanoma,” Nature, vol. 547, no. 7662, pp. 217–221, 2017.

J. P. W. Heidbuchel and C. E. Engeland, “Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies,” Journal of Hematology & Oncology, vol. 14, no. 6, pp. 1808–1820, 2021.
[90] E. J. Kelly, E. M. Hadac, S. Greiner, and S. J. Russell, "Engineering microRNA responsiveness to decrease virus pathogenicity," *Nature Medicine*, vol. 14, no. 11, pp. 1278–1283, 2008.

[91] C. A. Alvarez-Breckenridge, J. Yu, M. A. Caligiuri, and E. A. Chiocca, "Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy," *Oncoimmunology*, vol. 2, no. 4, article e23658, 2013.

[92] R. Carlisle, J. Choi, M. Bazan-Peregrino et al., "Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound," *Journal of the National Cancer Institute*, vol. 105, no. 22, pp. 1701–1710, 2013.

[93] J. Kim, R. R. Hall, M. S. Lesniak, and A. U. Ahmed, "Stem cell-based cell carrier for targeted oncolytic virotherapy: translational opportunity and open questions," *Viruses*, vol. 7, no. 12, pp. 6200–6217, 2015.

[94] S. Tang, Q. Ning, L. Yang, Z. Mo, and S. Tang, "Mechanisms of immune escape in the cancer immune cycle," *International Immunopharmacology*, vol. 86, article 106700, 2020.

[95] Q. Ning, Y. F. Liu, P. J. Ye et al., "Delivery of liver-specific miRNA-122 using a targeted macromolecular prodrug toward synergistic therapy for hepatocellular carcinoma," *ACS Applied Materials & Interfaces*, vol. 11, no. 11, pp. 10578–10588, 2019.